Gonadorelin

GnRH · Gonadotropin-Releasing Hormone · Lutrepulse · LHRH

"The master switch of the reproductive axis — a decapeptide released every 90 minutes from your hypothalamus to tell your pituitary to make LH and FSH. Became the primary TRT companion peptide after HCG was reclassified as a biologic in 2020. Nobel Prize 1977. Pulsatile dosing is everything — continuous infusion paradoxically shuts testosterone down."

Structure

10 AA decapeptide · identical to endogenous GnRH

Half-life

2–4 minutes · requires frequent dosing

TRT use

100–200mcg SubQ twice daily · ~$15–20/month

vs HCG

Works upstream · stimulates both LH and FSH

FDA status

Approved for diagnostic + hypothalamic amenorrhea

Protocol summary

Dose

50–200 mcg per injection

Frequency

2–3× weekly SubQ

Half-life

2–10 minutes (very short)

Use case

TRT companion, fertility

How we read the evidence

Synthetic GnRH · short half-life requires pulsatile dosing · less reliable than HCG for testicular preservation but cleaner mechanism

Animal evidence

Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH). The biology — pulsatile GnRH triggering pituitary release of LH and FSH which then stimulate gonadal function — is one of the most fundamental and well-understood endocrine pathways. Animal work established the requirement for pulsatile rather than continuous administration: continuous GnRH agonism causes pituitary receptor desensitisation and gonadotropin suppression (the basis of leuprolide cancer therapy), while pulsatile dosing preserves natural signalling.

Community & clinical practice

Community protocols converge on 50–200 mcg SubQ 2–3 times weekly on non-consecutive days (Mon/Wed/Fri pattern) when used as a TRT companion to maintain testicular function and fertility. Half-life is very short (2–10 minutes), so the pulse is brief and the dosing schedule mimics natural pulsatile GnRH release rather than producing sustained levels. Some intensive fertility protocols use 6× daily dosing at 5–20 mcg via infusion pump. Daily dosing should be limited to ≤14 consecutive days to preserve pituitary sensitivity.

Human trial data

Decades of clinical use in fertility medicine — gonadorelin has been used for diagnostic GnRH testing and for treating hypogonadotropic hypogonadism via pulsatile pump infusion. The TRT-companion application is more recent off-label practice without dedicated RCTs. Honest read: HCG has decades of clinical data for maintaining testicular volume and fertility in TRT; gonadorelin is the newer option that some clinics switched to when HCG access became uncertain. Gonadorelin doesn't reliably maintain intratesticular testosterone or sperm production in men whose HPG axis is significantly suppressed by TRT — for those goals, HCG is typically more effective.

Regulatory status

Approved in some markets as Lutrelef (pulsatile pump) and as a diagnostic agent. Not specifically approved for TRT-companion use — that's off-label. Available via compounding pharmacies in the US for fertility/HRT applications. WADA does not list gonadorelin specifically.

Convergence

Gonadorelin is a legitimate off-label TRT companion with a clean mechanism, but evidence for its TRT-companion use is more limited than for HCG. Standard protocol is 50–200 mcg SubQ 2–3× weekly on non-consecutive days. Some men respond well; others don't respond adequately even with frequent dosing. Pep IQ flags this honestly: gonadorelin works for some, not all, and HCG remains the more clinically validated option where access permits. The short half-life means single doses produce brief effects rather than sustained gonadal stimulation.

Community-reported

100–200 mcg SubQ twice daily (TRT companion)

Off-label TRT use; replaces HCG for some

Origin & Background

The hypothalamic master switch — and the Nobel Prize it earned

Gonadorelin is a synthetic decapeptide chemically identical to endogenous gonadotropin-releasing hormone (GnRH) — the ten-amino-acid peptide your hypothalamus releases in precise pulses every ~90 minutes to regulate the entire reproductive axis. Its discovery earned Andrew Schally and Roger Guillemin the Nobel Prize in Physiology or Medicine in 1977, recognising it as one of the most consequential findings in 20th-century endocrinology.

GnRH travels the short portal blood supply from hypothalamus to anterior pituitary, where it binds GnRH receptors on gonadotroph cells and triggers the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH). LH signals Leydig cells in the testes to produce testosterone; FSH drives spermatogenesis. In women, the same cascade controls oestrogen production, follicular development, and ovulation timing. Gonadorelin is the upstream master — everything downstream depends on it.

For the TRT community, gonadorelin became newly important after 2020. The FDA reclassified human chorionic gonadotropin (HCG) as a biologic, removing it from compounding pharmacy availability and making it significantly harder to access. HCG had been the standard TRT companion for decades — used to keep testicular function active while on exogenous testosterone. Gonadorelin stepped into that gap as the primary compoundable alternative, offering a different mechanism at a fraction of the cost (~$15–20/month vs $50–150+/month for HCG).

The pulsatile paradox: Continuous GnRH exposure does the opposite of pulsatile — it downregulates GnRH receptors on pituitary gonadotrophs and paradoxically suppresses LH, FSH, and testosterone. This is the basis for GnRH agonists like leuprolide used in prostate cancer treatment. For fertility and TRT applications, pulsatile delivery is not just preferred — it is pharmacologically essential. Get this wrong and gonadorelin actively suppresses the axis it's meant to preserve.

Science & Mechanism

Working upstream — how it differs from HCG

Mechanism of Action

GnRH receptor binding (pituitary gonadotrophs): Gonadorelin binds the GnRH receptor — a Gq/11-coupled GPCR — on pituitary gonadotroph cells. This activates phospholipase C → IP3 → intracellular calcium → protein kinase C → synthesis and secretion of LH and FSH. With pulsatile dosing, this cascade fires and resets every injection cycle, maintaining receptor sensitivity.

LH → testosterone (Leydig cells): Released LH travels to the testes and binds LH receptors on Leydig cells, stimulating the cAMP pathway → StAR protein activation → cholesterol conversion → testosterone synthesis. This is the same signal testosterone replacement suppresses via negative feedback at the hypothalamus and pituitary.

FSH → spermatogenesis (Sertoli cells): FSH binds Sertoli cell receptors in the testes, supporting spermatogenesis, seminiferous tubule integrity, and testicular volume. This is gonadorelin's key advantage over HCG — HCG only mimics LH, whereas gonadorelin stimulates both LH and FSH, preserving sperm production alongside testosterone.

vs HCG — upstream vs downstream: HCG mimics LH directly at the Leydig cell level — it bypasses the hypothalamic-pituitary axis entirely and works even if the pituitary is suppressed. Gonadorelin works upstream, requiring an intact and responsive pituitary to produce any effect. If the pituitary is damaged or sufficiently suppressed by TRT, gonadorelin may not work — HCG remains the only option in those cases.

Receptor desensitisation risk: With twice-daily SubQ injections, each dose creates a brief pulsatile stimulus followed by receptor reset. This mimics the natural ~90-minute hypothalamic pulse pattern well enough to maintain pituitary responsiveness. Daily dosing is insufficient; continuous infusion is counterproductive.

Individual response to gonadorelin on TRT varies significantly. Some men maintain excellent testicular volume and LH/FSH output on 100–200mcg twice daily; others respond minimally even at higher doses. The degree of HPG axis suppression from exogenous testosterone, individual pituitary responsiveness, and duration of TRT all affect outcomes. Clinicians who prescribe both note that gonadorelin is most predictable for testicular volume maintenance — it is less reliable than HCG for maintaining intratesticular testosterone levels and spermatogenesis in men who need definitive fertility preservation.

Benefits & Evidence

What the data shows

🔬

Hypothalamic amenorrhea / hypogonadotropic hypogonadism

FDA-approved via pulsatile pump for hypothalamic amenorrhea and hypothalamic hypogonadism. Pulsatile GnRH pump protocols achieve ovulation in ~96% of cycles in HA patients. Gold standard mechanistic treatment — restores the endogenous axis rather than bypassing it.

● Strong — FDA-approved indication · RCT data

⚾

Testicular preservation on TRT

Widely used clinically; LH and FSH become measurable on bloodwork in most responders. Testicular volume maintenance reported by majority of users. Less predictable than HCG — some men don't respond. Works best in men with intact pituitary function whose HPG axis is not fully suppressed.

● Moderate — clinical use data · variable individual response

👶

Fertility preservation — FSH advantage

Unique advantage over HCG: gonadorelin stimulates both LH and FSH. FSH is required for spermatogenesis. HCG only mimics LH, leaving FSH suppressed on TRT. For men on TRT who want to preserve sperm production, gonadorelin's FSH stimulation is mechanistically superior — though practical outcomes data is limited.

● Moderate — mechanistic advantage · limited RCT in TRT context

🧪

HPG axis diagnostic

FDA-approved for pituitary function testing. A single injection of gonadorelin with LH/FSH measured at 30 and 60 minutes distinguishes hypothalamic from pituitary hypogonadism — still used in endocrinology clinics for diagnostic purposes.

● Strong — FDA-approved diagnostic use